| Product NDC: | 53104-0105 |
| Proprietary Name: | zidovudine |
| Non Proprietary Name: | zidovudine |
| Active Ingredient(s): | 50 mg/5mL & nbsp; zidovudine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | SYRUP |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 53104-0105 |
| Labeler Name: | Cipla Limited |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA077981 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20080626 |
| Package NDC: | 53104-0105-4 |
| Package Description: | 100 mL in 1 BOTTLE (53104-0105-4) |
| NDC Code | 53104-0105-4 |
| Proprietary Name | zidovudine |
| Package Description | 100 mL in 1 BOTTLE (53104-0105-4) |
| Product NDC | 53104-0105 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | zidovudine |
| Dosage Form Name | SYRUP |
| Route Name | ORAL |
| Start Marketing Date | 20080626 |
| Marketing Category Name | ANDA |
| Labeler Name | Cipla Limited |
| Substance Name | ZIDOVUDINE |
| Strength Number | 50 |
| Strength Unit | mg/5mL |
| Pharmaceutical Classes | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |